Clinical significance of the ubiquitin ligase UBE3C in hepatocellular carcinoma revealed by exome sequencing

Hepatology

Volumn 59, Issue 6, 2014, Pages 2216-2227

  Jiang, Jia Hao ^a   Liu, Yan Feng ^b   Ke, Ai Wu ^a   Gu, Fang Ming ^a   Yu, Yao ^a   Dai, Zhi ^a   Gao, Qiang ^a   Shi, Guo Ming ^a   Liao, Bo Yi ^a   Xie, You Hua ^b   Fan, Jia ^a,c   Huang, Xiao Wu ^a,c   Zhou, Jian ^a,c  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Shanghai Key Laboratory of Organ Transplantation   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TRANSCRIPTION FACTOR SNAIL; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3C; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXOME; EXON; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; INDEL MUTATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MISSENSE MUTATION; MUTATION RATE; PHYLOGENY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RNA INTERFERENCE; SOMATIC MUTATION; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME; UPREGULATION;

AMINO ACID SUBSTITUTION; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE PROGRESSION; EXOME; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PROGNOSIS; SEQUENCE ANALYSIS, DNA; UBIQUITIN-PROTEIN LIGASES;

EID: 84901430226     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27012     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
3. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 2012;62:394-399.
4. McGlynn KA, Edmonson MN, Michielli RA, London WT, Lin WY, Chen GC, et al. A phylogenetic analysis identifies heterogeneity among hepatocellular carcinomas. Hepatology 2002;36:1341-1348.
5. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346.
6. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006;25:3778-3786.
7. Yeh SH, Chen PJ, Shau WY, Chen YW, Lee PH, Chen JT, et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 2001;121:699-709.
8. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
9. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-687.
10. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012;44:760-764.
11. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011;43:828-829.
12. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012;44:1117-1121.
13. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 2009;49:491-503.
14. Huang L, Kinnucan E, Wang G, Beaudenon S, Howley PM, Huibregtse JM, et al. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 1999;286:1321-1326.
15. Croce CM. Molecular origins of cancer: oncogenes and cancer. N Engl J Med 2008;358:502-511.
16. Taguchi K, Aishima S, Matsuura S, Terashi T, Nishiyama K, Shirabe K, et al. Significance of the relationship between irregular regeneration and two hepatocarcinogenic pathways: "de novo" and so-called "dysplastic nodule-hepatocellular carcinoma" sequence. J Surg Oncol 2005;92:100-103.
17. Kobayashi M, Ikeda K, Hosaka T, Sezaki H, Someya T, Akuta N, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 2006;106:636-647.
18. Miller S, Rogers HA, Lyon P, Rand V, Adamowicz-Brice M, Clifford SC, et al. Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro Oncol 2011;13:866-879.
19. Renz M, Betz B, Niederacher D, Bender HG, Langowski J. Invasive breast cancer cells exhibit increased mobility of the actin-binding protein CapG. Int J Cancer 2008;122:1476-1482.
20. De Corte V, Van Impe K, Bruyneel E, Boucherie C, Mareel M, Vandekerckhove J, et al. Increased importin-beta-dependent nuclear import of the actin modulating protein CapG promotes cell invasion. J Cell Sci 2004;117:5283-5292.
21. Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 2013;23:1422-1433.
22. Ikeda A, Shimizu T, Matsumoto Y, Fujii Y, Eso Y, Inuzuka T, et al. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associate with hepatocellular carcinoma. Gastroenterology 2013 [Epub ahead of print].
23. Nishida N, Kudo M. Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. Oncology 2013;84(Suppl 1):93-97.
24. Metzger MB, Hristova VA, Weissman AM. HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci 2012;125:531-537.
25. Rotin D, Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 2009;10:398-409.
26. Basel-Vanagaite L, Dallapiccola B, Ramirez-Solis R, Segref A, Thiele H, Edwards A, et al. Deficiency for the ubiquitin ligase UBE3B in a blepharophimosis-ptosis-intellectual-disability syndrome. Am J Hum Genet 2012;91:998-1010.
27. Mashimo T, Hadjebi O, Amair-Pinedo F, Tsurumi T, Langa F, Serikawa T, et al. Progressive Purkinje cell degeneration in tambaleante mutant mice is a consequence of a missense mutation in HERC1 E3 ubiquitin ligase. PLoS Genet 2009;5:e1000784.
28. Malzac P, Webber H, Moncla A, Graham JM, Kukolich M, Williams C, et al. Mutation analysis of UBE3A in Angelman syndrome patients. Am J Hum Genet 1998;62:1353-1360.
29. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
30. Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB, et al. CD151 amplifies signaling by integrin alpha6beta1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology 2011;140:1629-1641 e1615.
31. Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008;14:10-21.
32. Rolfe M, Beer-Romero P, Glass S, Eckstein J, Berdo I, Theodoras A, et al. Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proc Natl Acad Sci U S A 1995;92:3264-3268.
33. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005;23:4776-4789.
34. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007;128:129-139.
35. Eide PW, Cekaite L, Danielsen SA, Eilertsen IA, Kjenseth A, Fykerud TA, et al. NEDD4 is overexpressed in colorectal cancer and promotes colonic cell growth independently of the PI3K/PTEN/AKT pathway. Cell Signal 2013;25:12-18.
36. Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, et al. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res 2003;63:4299-4304.
37. Anglesio MS, Evdokimova V, Melnyk N, Zhang L, Fernandez CV, Grundy PE, et al. Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum Mol Genet 2004;13:2061-2074.
38. Chen C, Zhou Z, Ross JS, Zhou W, Dong JT. The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer 2007;121:80-87.
39. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009;458:438-444.
40. Micel LN, Tentler JJ, Smith PG, Eckhardt GS. Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol 2013;31:1231-1238.